Freedom from Cancer Startup Challenge
  • Home
  • Winners
  • Overview
    • Key Dates
    • Phase 0 - Enter Challenge
    • Phase 1 - Elevator Speech
    • Phase 2 - Business Plan
    • Phase 3 - Start-up
  • Mavens
    • Ambassadors
    • Apply as Maven
  • About Us
    • Contact Us
    • Testimonials
    • News
    • Blog
  • Home
  • Winners
  • Overview
    • Key Dates
    • Phase 0 - Enter Challenge
    • Phase 1 - Elevator Speech
    • Phase 2 - Business Plan
    • Phase 3 - Start-up
  • Mavens
    • Ambassadors
    • Apply as Maven
  • About Us
    • Contact Us
    • Testimonials
    • News
    • Blog
Search by typing & pressing enter

YOUR CART

RETURN TO ALL INVENTIONS LIST
RETURN TO DIAGNOSTICS LIST
Assays for determining the effect of an immune cell on a cell from an infectious or neoplastic disease
Patent Number: US9488644

Executive Summary:
  • Invention Type: Diagnostic
  • Patent Status: US Grant
  • Patent Link: https://patents.google.com/patent/US9488644/
  • Research Institute: Columbia University
  • Disease Focus: Cancers, including melanoma, and infectious diseases
  • Basis of Invention: In vitro assay to measure the cytolytic activity of ex-vivo-expended CD8+ T-cells and determine the concentration of CD8+ T-cells to infuse into the patient
  • How it works: Cells from a neoplastic (or infectious) disease and CD8+ T-cells are cultured in a three-dimensional collagen-fibrin gel in vitro, to assess CD8+ T-cell cytolytic activity. A clonogenic assay is used to measure cell viability and determine a value for the critical concentration of T-cells required to kill cells from a neoplastic (or infectious) disease
  • Lead Challenge Inventor: Samuel C. Silverstein
  • Inventors: John D. Loike, Sadna Budhu, Peter P. Lee, Samuel C. Silverstein
  • Development Stage: Preclinical
  • Novelty:
    • Concomitant evaluation of the cytolytic activity of ex-vivo-activated CD8+ T-cells and determination of the concentration of CD8+ T-cells to infuse into the patient to efficiently kill cancer cells
  • Clinical Applications:
    • Adoptive T-cell therapy for the treatment of cancer and infectious diseases

General Description:
This is a quantitative model for assessing the cytolytic activity of CD8+ T-cells in a collagen-fibrin gels combined with a clonogenic assay for cancer cells. An equation is applied to calculate the critical concentration of CD8+ T-cells to kill cancer cells in vitro and in vivo.

Scientific Progress:
The assay has been developed with primary mouse CD8+ T-cell and mouse melanoma cells. The equation to calculate the optimal T-cell concentration to infuse has been validated in vivo.

Future Directions:
  • Validation with primary human CD8+ T-cells isolated from peripheral blood
  • Clinical proof-of-concept of the equation to calculate the critical concentration of T-cells to infuse into patients

Strengths:
  • The combination of the evaluation of the cytolytic activity of T-cells, their ex-vivo expansion, and the determination of the optimal concentration of T-cells to kill cancer cells

Weaknesses:
  • Competition with the numerous assays on the market that measure T-cell activation

Patent Status:
Legal Status: Active, expire 2031.06.20
  • Priority date: 2009.11.11
  • Filing date: 2010.11.11
  • Publication date: 2016.11.08
  • Grant date: 2016.11.08

Publication PMID: 20065066
 
Publication:
Budhu S, Loike JD, Pandolfi A, Han S, Catalano G, Constantinescu A, Clynes R, Silverstein SC. CD8+ T-cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med. 2010 Jan 18;207(1):223-35. doi: 10.1084/jem.20091279. Epub 2010 Jan 11.
 
Inventor Bio: Samuel C. Silverstein
http://www.physiology.columbia.edu/SamuelCSilverstein.html
Powered by Create your own unique website with customizable templates.